Science 37 Stock Price, News & Analysis (NASDAQ:SNCE) $0.25 0.00 (0.00%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$0.23▼$0.2650-Day Range$0.24▼$0.4252-Week Range$0.19▼$0.69Volume367,158 shsAverage Volume788,613 shsMarket Capitalization$29.85 millionP/E RatioN/ADividend YieldN/APrice Target$1.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Science 37 MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside300.0% Upside$1.00 Price TargetShort InterestBearish2.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector568th out of 952 stocksCommercial Physical Research Industry10th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingScience 37 has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.00, Science 37 has a forecasted upside of 300.0% from its current price of $0.25.Amount of Analyst CoverageScience 37 has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.06% of the float of Science 37 has been sold short.Short Interest Ratio / Days to CoverScience 37 has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Science 37 has recently increased by 50.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldScience 37 does not currently pay a dividend.Dividend GrowthScience 37 does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNCE. Previous Next 1.9 News and Social Media Coverage News SentimentScience 37 has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Science 37 this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SNCE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Science 37 to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Science 37 insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Science 37 is held by insiders.Percentage Held by Institutions40.67% of the stock of Science 37 is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Science 37 are expected to grow in the coming year, from ($0.55) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Science 37 is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Science 37 is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScience 37 has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Science 37 Stock (NASDAQ:SNCE)Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.Read More SNCE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNCE Stock News HeadlinesNovember 12, 2023 | finance.yahoo.comScience 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | finance.yahoo.comIt's Down 28% But Science 37 Holdings, Inc. (NASDAQ:SNCE) Could Be Riskier Than It LooksDecember 4, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 8, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Science 37 (SNCE), Guardant Health (GH)November 7, 2023 | msn.comScience 37 reports mixed Q3 earnings; initiates Q4 and updates FY23 outlookNovember 7, 2023 | finance.yahoo.comScience 37 Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comScience 37 Holdings Inc (SNCE) Reports Q3 2023 Financial ResultsNovember 6, 2023 | markets.businessinsider.comWhat Wall Street expects from Science 37's earningsDecember 4, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 24, 2023 | finance.yahoo.comScience 37 to Report Third Quarter 2023 Financial Results on November 7, 2023September 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Science 37 (SNCE)September 20, 2023 | finance.yahoo.comScience 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 ListSeptember 12, 2023 | finance.yahoo.comScience 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & SullivanSeptember 5, 2023 | finance.yahoo.comScience 37 to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | finance.yahoo.comScience 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA AwardsAugust 13, 2023 | barrons.comScience 37 Holdings Inc.August 11, 2023 | finance.yahoo.comIncreasing losses over year doesn't faze Science 37 Holdings (NASDAQ:SNCE) investors as stock rallies 122% this past weekAugust 9, 2023 | investing.comScience 37 Holdings (SNCE) Earnings Dates & ReportsAugust 8, 2023 | finanznachrichten.deScience 37, Inc.: Science 37 Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | msn.comScience 37 GAAP EPS of -$0.17 misses by $0.02, revenue of $15.35M beats by $2.78MAugust 8, 2023 | finance.yahoo.comScience 37 Reports Second Quarter 2023 Financial ResultsAugust 7, 2023 | benzinga.comScience 37 Hldgs Earnings PreviewJuly 25, 2023 | finance.yahoo.comScience 37 to Report Second Quarter 2023 Financial Results on August 8, 2023July 11, 2023 | finance.yahoo.comSynlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)July 11, 2023 | finance.yahoo.comSynlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)July 8, 2023 | finanznachrichten.deScience 37, Inc.: Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)May 18, 2023 | finance.yahoo.comScience 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"See More Headlines Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/04/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNCE CUSIPN/A CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees460Year FoundedN/APrice Target and Rating Average Stock Price Target$1.00 High Stock Price Target$1.00 Low Stock Price Target$1.00 Potential Upside/Downside+299.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,990,000.00 Net Margins-206.86% Pretax Margin-207.00% Return on Equity-83.09% Return on Assets-61.58% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$70.15 million Price / Sales0.43 Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book0.30Miscellaneous Outstanding Shares119,400,000Free Float111,278,000Market Cap$29.86 million OptionableNot Optionable Beta0.48 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David Coman (Age 53)CEO & Director Comp: $796.13kMs. Christine A. Pellizzari J.D. (Age 55)Chief Legal & Human Resources Officer and Secretary Comp: $521.58kMs. Darcy Forman (Age 47)Chief Delivery Officer Comp: $550.58kMr. Mike Zaranek (Age 52)Chief Financial Officer Irena LambridisVP and Head of Quality Assurance & ComplianceMs. Margie Gimbel KoomanVice President of Marketing & CommunicationsMr. Drew BustosChief Strategy & Marketing OfficerMr. Jonathan Cotliar M.D. (Age 51)Chief Medical Officer Comp: $486.6kMr. Michael Shipton (Age 51)Chief Commercial Officer Mr. Tyler Van HornVP of Corporate Strategy & Chief of StaffMore ExecutivesKey CompetitorsData Knights AcquisitionNASDAQ:DKDCAbioAffinity TechnologiesNASDAQ:BIAFAIkido PharmaNASDAQ:AIKIInotivNASDAQ:NOTVEledon PharmaceuticalsNASDAQ:ELDNView All CompetitorsInstitutional OwnershipKent Lake Capital LLCBought 1,084,471 shares on 11/15/2023Ownership: 0.908%Boston PartnersBought 268,882 shares on 11/8/2023Ownership: 1.193%View All Institutional Transactions SNCE Stock Analysis - Frequently Asked Questions Should I buy or sell Science 37 stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNCE shares. View SNCE analyst ratings or view top-rated stocks. What is Science 37's stock price target for 2024? 1 brokers have issued 12-month target prices for Science 37's stock. Their SNCE share price targets range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price. View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts. How have SNCE shares performed in 2023? Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE stock has decreased by 39.8% and is now trading at $0.25. View the best growth stocks for 2023 here. Are investors shorting Science 37? Science 37 saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,630,000 shares, an increase of 50.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 209,600 shares, the days-to-cover ratio is currently 7.8 days. Currently, 2.1% of the shares of the stock are short sold. View Science 37's Short Interest. When is Science 37's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our SNCE earnings forecast. How were Science 37's earnings last quarter? Science 37 Holdings, Inc. (NASDAQ:SNCE) issued its earnings results on Tuesday, November, 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $14.89 million for the quarter, compared to the consensus estimate of $14.70 million. Science 37 had a negative net margin of 206.86% and a negative trailing twelve-month return on equity of 83.09%. Who are Science 37's major shareholders? Science 37's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boston Partners (1.19%) and Kent Lake Capital LLC (0.91%). View institutional ownership trends. How do I buy shares of Science 37? Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SNCE) was last updated on 12/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.